Redirecting the focus of cancer immunotherapy to premalignant conditions
- PMID: 28130162
- PMCID: PMC5925415
- DOI: 10.1016/j.canlet.2017.01.022
Redirecting the focus of cancer immunotherapy to premalignant conditions
Abstract
Much progress has been made in introducing immunological treatment approaches for cancer, with lessons learned from both the successes and failures of immunotherapy. Among the challenges of immunotherapeutic approaches for cancer are the multitudes of mechanisms by which cancers are known to subvert the immune defenses. This has led to the incorporation into the immunotherapeutic arsenal strategies by which to overcome the cancer's immunological blockades. What has been only superficially explored is the immunological milieu of premalignant lesions and the possibility of immunological approaches for the treatment of premalignant lesions so as to prevent secondary premalignant lesions and their progression to cancer. This review discusses the immunological environment associated with premalignant lesions, and the possible missed opportunity of utilizing immunological treatment strategies in the less hostile environment of premalignant lesions as compared to the immune subversive cancer environment.
Keywords: Cancer; Immune infiltrate; Immunotherapy; Premalignant.
Published by Elsevier B.V.
Conflict of interest statement
None to declare.
Similar articles
-
Endoscopic mucosal resection for squamous premalignant and early malignant lesions of the esophagus.Endoscopy. 2007 Jan;39(1):24-9. doi: 10.1055/s-2006-945182. Endoscopy. 2007. PMID: 17252456
-
Review of squamous premalignant vulvar lesions.Crit Rev Oncol Hematol. 2008 Nov;68(2):131-56. doi: 10.1016/j.critrevonc.2008.02.012. Epub 2008 Apr 11. Crit Rev Oncol Hematol. 2008. PMID: 18406622 Review.
-
Malignant and premalignant skin conditions.Practitioner. 2003 Feb;247(1643):104-7, 109, 112-4 passim. Practitioner. 2003. PMID: 12621803 Review. No abstract available.
-
Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings.Head Neck. 2009 Aug;31(8):1039-48. doi: 10.1002/hed.21071. Head Neck. 2009. PMID: 19340865
-
[Present treatment modalities for premalignant and malignant lesions, for example, planocellular carcinoma of the mouth].Ned Tijdschr Tandheelkd. 1985;92 Spec No:429-33. Ned Tijdschr Tandheelkd. 1985. PMID: 3867830 Dutch. No abstract available.
Cited by
-
A novel mechanism of tumor-induced thymic atrophy in mice bearing H22 hepatocellular carcinoma.Cancer Manag Res. 2018 Mar 5;10:417-424. doi: 10.2147/CMAR.S157512. eCollection 2018. Cancer Manag Res. 2018. PMID: 29551914 Free PMC article.
-
Eosinophils: An imperative histopathological prognostic indicator for oral squamous cell carcinoma.J Oral Maxillofac Pathol. 2019 May-Aug;23(2):307. doi: 10.4103/jomfp.JOMFP_111_19. J Oral Maxillofac Pathol. 2019. PMID: 31516251 Free PMC article.
-
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.Front Immunol. 2020 Feb 11;11:159. doi: 10.3389/fimmu.2020.00159. eCollection 2020. Front Immunol. 2020. PMID: 32117295 Free PMC article. Review.
-
Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial.BMC Cancer. 2021 May 17;21(1):561. doi: 10.1186/s12885-021-08297-3. BMC Cancer. 2021. PMID: 34001010 Free PMC article.
-
Advances and challenges in cancer immunoprevention and immune interception.J Immunother Cancer. 2024 Mar 21;12(3):e007815. doi: 10.1136/jitc-2023-007815. J Immunother Cancer. 2024. PMID: 38519057 Free PMC article. Review.
References
-
- Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–287. - PubMed
-
- Perez SA, Karamouzis MV, Skarlos DV, Ardavanis A, Sotiriadou NN, Iliopoulou EG, et al. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res. 2007;13(9):2714–2721. - PubMed
-
- Park T, Choi CJ, Choi Y, Suh DC. Cost-effectiveness of cetuximab for colorectal cancer. Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):667–677. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases